Brokerages Set Abeona Therapeutics Inc (NASDAQ:ABEO) PT at $18.50

Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) has been assigned a consensus recommendation of "Buy" from the five ratings firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $18.50.

Several analysts recently weighed in on ABEO shares. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. HC Wainwright lifted their price objective on Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. Stifel Nicolaus decreased their price objective on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a report on Friday, May 16th. Oppenheimer started coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price objective for the company. Finally, Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th.

Insider Transactions at Abeona Therapeutics

In related news, Director Mark Alvino sold 8,000 shares of the company's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $5.68, for a total value of $45,440.00. Following the sale, the director now owns 92,435 shares in the company, valued at $525,030.80. This represents a 7.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total value of $119,500.00. Following the completion of the sale, the chief executive officer now owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. This represents a 1.81% decrease in their position. The disclosure for this sale can be found here. Insiders own 6.90% of the company's stock.

Institutional Investors Weigh In On Abeona Therapeutics

A number of large investors have recently bought and sold shares of the company. OMERS ADMINISTRATION Corp boosted its position in Abeona Therapeutics by 11.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock valued at $344,000 after buying an additional 7,155 shares during the last quarter. Twinbeech Capital LP purchased a new stake in Abeona Therapeutics in the 4th quarter worth approximately $58,000. Northern Trust Corp boosted its position in Abeona Therapeutics by 6.6% in the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock worth $1,030,000 after purchasing an additional 11,478 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Abeona Therapeutics in the 4th quarter worth approximately $67,000. Finally, Cannon Global Investment Management LLC purchased a new stake in Abeona Therapeutics in the 1st quarter worth approximately $67,000. Hedge funds and other institutional investors own 80.56% of the company's stock.

Abeona Therapeutics Trading Down 2.4%

Shares of NASDAQ:ABEO traded down $0.16 on Monday, hitting $6.42. 957,198 shares of the company's stock were exchanged, compared to its average volume of 619,860. Abeona Therapeutics has a 12 month low of $3.93 and a 12 month high of $7.32. The stock has a market capitalization of $328.43 million, a price-to-earnings ratio of -2.39 and a beta of 1.68. The business's 50 day simple moving average is $5.29 and its two-hundred day simple moving average is $5.56. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.11. Analysts anticipate that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.